Form 4: United Therapeutics Director Rothblatt Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4
Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 28 and 29, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, a director at United Therapeutics Corp, engaged in transactions involving the company's stock on May 28 and May 29, 2024.
- These transactions involved the exercise of stock options and the subsequent sale of common stock.
- The exercises and sales were conducted under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both May 28 and 29, 3,600 stock options were exercised at a price of $129.49 per share.
- Following the exercise of options on May 28, shares were sold in multiple transactions at weighted average prices of $267.7687, $268.7847, $269.5359, and $271.262.
- Following the exercise of options on May 29, shares were sold in multiple transactions at weighted average prices of $265.2222, $265.9704, $267.5931, and $268.3523.
- The reporting person also holds shares indirectly through various family trusts.
- After the reported transactions, Rothblatt directly owns 216,269 derivative securities and between 130 and 3,730 shares of common stock.
- Rothblatt indirectly owns between 166 and 324,518 shares of common stock through various trusts.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing plan. There's no indication of positive or negative outlook.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 723,869 stock options that expire December 31, 2024, or August 31, 2024.
Industry Context
Executive stock sales are common and often pre-planned using 10b5-1 plans to avoid accusations of insider trading. These plans allow insiders to sell shares at predetermined times and prices.
Comparison to Industry Standards
- Comparing Rothblatt's transactions to other directors' dealings in similar biotech firms, the use of a 10b5-1 plan is a standard practice.
- Companies like Amgen and Gilead Sciences also see frequent insider transactions under similar plans.
- The size of the tranche (723,869 options) is substantial but not unusual for long-tenured executives in large biotech companies.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Date stock options were exercisable |
| 08/04/2023 | Date the 10b5-1 trading plan was entered into by the reporting person |
| 05/28/2024 | Date of first transaction (exercise and sale of stock) |
| 05/29/2024 | Date of second transaction (exercise and sale of stock) |
| 05/30/2024 | Date of signing of the Form 4 filing |
| 08/31/2024 | End date of the 10b5-1 trading plan (unless tranche is exhausted earlier) |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.